Geron Corporation Says FDA Halts Patient Enrollment In Another Cancer Trial

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Geron Corp said the U.S. Food and Drug Administration ordered a halt to new patient enrollments in an early-stage trial of its blood cancer drug, imetelstat, over concerns about liver damage. The halt announced on Thursday was for enrollments in a trial sponsored by Mayo Clinic, and comes a week after the FDA ordered Geron to cease company-sponsored trials of the drug over similar concerns. Imetelstat is Geron’s only remaining drug and was touted as the company’s savior after curing 22 percent of myelofibrosis patients in a trial last year.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC